The Wnt pathway: Emerging anticancer strategies

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 7, Issue 2, 2013, Pages 138-147

  Gupta, Aman ^a   Verma, Anukriti ^a   Mishra, Ashutosh K ^a   Wadhwa, Gulshan ^b   Sharma, Sanjeev K ^a   Jain, Chakresh K ^a  

^a JAYPEE INSTITUTE OF INFORMATION TECHNOLOGY   (India)

^b DEPARTMENT OF BIOTECHNOLOGY   (India)

Author keywords

catenin; TrCP; Adenomatous polypolis coli (APC); AML; Axin; Casein kinase 1 (CK1 ); Dishevelled (Dsh); Frat1; GSK 3 (Glycogen synthase kinase 3 ); PLC (phospholipase C); Wnt

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; DISHEVELLED PROTEIN; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; ICG 001; IWR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MUCIN 1; NSC 668036; PYRVINIUM EMBONATE; UNCLASSIFIED DRUG; WNT PROTEIN; XAV 939;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER DIAGNOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL MEMBRANE; CELL NUCLEUS; CELL POLARITY; COLORECTAL CANCER; CONFORMATIONAL TRANSITION; CYTOPLASM; ENDOCYTOSIS; GROWTH; HUMAN; NONHUMAN; PATENT; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN FAMILY; TRANSACTIVATION; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM SIGNALING; DRUG DESIGN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATENTS AS TOPIC; WNT SIGNALING PATHWAY;

EID: 84876709382     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872214811307020007     Document Type: Article

References (57)

1. Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of ßβ-catenin-independent Wnt signalling. Dev Cell 2003; 5: 367-77.
2. Mlodzik M. Planar cell polarization: Do the same mechanisms regulate Drosophila tissue polarity and vertebrate gastrulation. Trends Genet 2002; 18: 564-71.
3. Vinson CR, Conover S, Adler PN. A Drosophila tissue polarity locus encodes a protein containing seven potential transmembrane domains. Nature 1989; 338: 26-4.
4. Katoh M, Katoh M. Comparative genomics between Drosophila and human. Genome Informatics 2003; 24: 587-8.
5. Adler PN. Planar signalling and morphogenesis in Drosophila. Dev Cell 2003; 2: 525-55.
6. Katoh M. Regulation of WNT signalling molecules by retinoic acid during neuronal differentiation in NT2 cells: Threshold model of WNT action. Int J Mol Med 2002; 10: 683-87.
7. Huang CH, Klein PS. The Frizzled family: Receptors for multiple signal transduction pathways. Genome Biol 2004; 5: 234-41.
8. Katoh M. WNT and FGF gene clusters. Int J Oncol 2002; 21: 1269-73.
9. Miller RJ. The Wnts. Genome Biol 2002; 3: 1-75.
10. Dale CT. Signal transduction by the Wnt family of ligands. Biochem J 1998; 329: 209-23.
11. Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, et al. Arrow encodes an LDL-receptor-related protein essential for wingless signalling. Nature 2000; 407: 527-30.
12. Mao J, Wang J, Liu B, Pan W, Farr GH 3rd, Flynn C, et al. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signalling pathway. Mol Cell 2001; 7: 801-9.
13. Amerongen RV, Berns A. Re-evaluating the role of Frat in Wnt-signal transduction. Cell Cycle 2005; 4(8): 1065-72.
14. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and betaβ-catenin signalling: Diseases and therapies. Nat Rev Genet 2004; 5: 691-701.
15. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, et al. The F-box protein beta-TrCP associates with phosphoryated betaβ-catenin and regulates its activity in the cell. Curr Biol 1997; 9: 207-10.
16. Liu C, Kato Y. β-Trcp couples bβ-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci 1999; 96: 6273-8.
17. Yuan H, Weaver CD, Mao J, Farr GH, Sussman D J, Jonkers J, Kimelman D, et al. Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J 1999; 18: 4233-40.
18. Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S, et al. Axin, a negative regulator of the Wnt signalling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of β-catenin. J Biol Chem 1998; 273: 10823-6.
19. Giles HR, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signalling in cancer. Biochimical Biophysica Acta 2003; 1653: 1-24.
20. Behrens J, Jerchow BA, Würtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an axin homolog, conductin, with betacatenin, APC, and GSK3beta. Science 1998; 280: 596-9.
21. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of Axin, a Wnt signal negative regulator, by glycogen synthase kinase-3 regulates its stability. J Biol Chem 1999; 274: 1068-4.
22. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO 2005; 24: 1571-83.
23. Peifer M, Polakis P. Wnt signalling in oncogenesis and embryo-genesis: A look outside the nucleus. Science 2000; 287: 1606-9.
24. Fodde R. The APC gene in colorectal cancer. Eur J Cancer 2002; 38: 867-71.
25. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates betaβ-catenin subcellular localization and turnover. Nat Cell Biol 2000; 2(9): 653-60.
26. Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a nuclear export function. Nature 2000; 406(6799): 1009-12.
27. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000; 14: 1553-77.
28. Wetering MV, Cavallo R, Dooijes D, van Beest M, van Es J, Loureiro J, et al. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 1997; 88(6): 789-99.
29. Brunner E, Peter O, Schweizer L, Basler K. Pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in Drosophila. Nature 1997; 385(6619): 829-33.
30. Brantjes H, Roose J, van De Wetering M, Clevers H. All Tcf HMG box transcription factors interact with Groucho-related corepressors. Nucleic Acids Res 2001; 29(7): 410-19.
31. Semenov MV, Habas R, MacDonald BT, He X. SnapShot: Non-canonical Wnt Signaling Pathways. Cell 2007; 131: 1378-9.
32. Sugimura R, Li L. Noncanonical Wnt signaling in vertebrate development, stem cells, and diseases. Birth Defects Res C Embryo Today 2010; 90: 243-56.
33. Katoh M, Katoh M.WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007; 13: 4042-45.
34. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, et al. Wnt/beta catenin signaling pathway as a novel cancer drug target. Curr. Cancer Drug Targets 2004; 4: 653-71.
35. Henderson WR, Chib EY. Inhibition of Wnt/ β-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. PNAS 2010; 107(32): 14309-14.
36. Thorne CA, Hanson AJ. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1. Nature Chem Biol 2010; 6: 829-36.
37. Huang SM, Mishina YM. Tankyrase inhibition stabilizes axin and antagonizes Wnt signaling. Nature 2009; 461: 614-20.
38. Chen B, Dodge ME. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chem Biol 2009; 5: 100-7.
39. Shan J, Shi DL, Wang J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005; 44(47): 15495-503.
40. Constantine, F. Axin gene and uses thereof. US6307019 (2001).
41. Xu, L. Compositions and methods of diagnosis and treatment using casein kinase I. US6512102 (2003).
42. He, B. Methods for treating cancer by inhibiting Wnt signalling. US20040247593 (2004).
43. You, L. Methods for treating and diagnosing cancer with WNT inhibitory Factor-1 (WIF-1). US7618936 (2009).
44. Gurney, A. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth. US7723477 (2010).
45. Hood, J. Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof. US8252812 (2012).
46. Berdini, V. 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators. US0213791 (2012).
47. Tyers, M. Method for treating a brain cancer with ifenprodil. US8058243 (2011).
48. Michelson, G.C. Methods for treating drug resistant cancer. US8299081 (2012).
49. Beachy, P.A. WNT pathway antagonists. US7652043 (2010).
50. Gurney, A.L. Frizzled-binding agents and uses thereof. US7982013 (2011).
51. Forster, C.J. Compositions useful as inhibitors of GSK-3. US7872129 (2011).
52. Wands, J.R. Wnt proteins and detection and treatment of cancer. US8158761 (2012).
53. Ernst, J.A. Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders. US7947277 (2011).
54. Munar, G.C. Method for the diagnosis of colorectal cancer. EP2363499 (2011).
55. Jones, S.N. Diagnosing and treating hematopoietic cancers. US7723055 (2010).
56. Ma, X.J. Monoclonal antibodies that inhibit the Wnt signalling pathway and methods of production and use thereof. US20120045437 (2012).
57. Schroeder, A.J. Therapeutic peptides for the treatment of metastatic cancer. US7767642 (2010).